Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
3180 Porter Drive
Palo Alto, CA 94304
Phone: (650) 496 3777Website: https://www.jazzpharma.com/Careers: careers.jazzpharma.com/jobsPatient Assistance Program: www.jazzpharma.com/responsibility...
Latest news
- Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
2 April 2024 - Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
2 June 2023 - Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
18 November 2022 - Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
12 August 2021 - FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
30 June 2021 - Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
30 March 2021 - FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
22 July 2020 - Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
22 January 2020 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
20 March 2019 - Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
21 December 2018
Drugs Associated with Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc manufactures, markets and/or distributes more than 10 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Defitelio
Generic name: defibrotide Drug class: miscellaneous coagulation modifiers |
||
|
Erwinaze
Generic name: asparaginase erwinia chrysanthemi Drug class: miscellaneous antineoplastics |
||
|
Prialt
Generic name: ziconotide Drug class: miscellaneous analgesics |
12 reviews | 4.0 / 10 |
|
Rylaze
Generic name: asparaginase erwinia chrysanthemi Drug class: miscellaneous antineoplastics |
||
|
Sunosi
Generic name: solriamfetol Drug class: miscellaneous central nervous system agents |
72 reviews | 5.1 / 10 |
|
Versacloz
Generic name: clozapine Drug class: atypical antipsychotics |
||
|
Vyxeos
Generic name: cytarabine liposomal/daunorubicin liposomal Drug class: antineoplastic combinations |
||
|
Xyrem
Generic name: sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
105 reviews | 7.7 / 10 |
|
Xywav
Generic name: calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
14 reviews | 8.0 / 10 |
|
Zepzelca
Generic name: lurbinectedin Drug class: alkylating agents |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
